{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:44:22Z","timestamp":1784360662342,"version":"3.55.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:00:00Z","timestamp":1482451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:00:00Z","timestamp":1482451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"name":"ACTTION public-private partnership"},{"name":"Department of Veterans Affairs (Biomedical and Laboratory Research Service and Rehabilitation Research and Development)","award":["101RX001030"],"award-info":[{"award-number":["101RX001030"]}]},{"name":"Baltimore Geriatric Research, Education, and Clinical Center (GRECC)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle Nerve"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1002\/mus.25264","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T22:47:01Z","timestamp":1469227621000},"page":"366-372","source":"Crossref","is-referenced-by-count":24,"title":["Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy"],"prefix":"10.1002","volume":"55","author":[{"given":"Jennifer S.","family":"Gewandter","sequence":"first","affiliation":[{"name":"University of Rochester; Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Burke","sequence":"additional","affiliation":[{"name":"LORA Group, LLC; Royal Oak Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca; Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[{"name":"University of Rochester; Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Harvard Medical School; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony D.","family":"Gover","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research and Materiel Command; Fort Detrick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"University of Rochester; Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Mcarthur","sequence":"additional","affiliation":[{"name":"Johns Hopkins University; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McDermott","sequence":"additional","affiliation":[{"name":"University of Rochester; Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob A.","family":"Rappaport","sequence":"additional","affiliation":[{"name":"Arlington; Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce B.","family":"Reeve","sequence":"additional","affiliation":[{"name":"University of North Carolina; Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Russell","sequence":"additional","affiliation":[{"name":"University of Maryland and Veterans Administration Maryland Health Care System; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Gordon","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Utah; Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Rochester; Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Turk","sequence":"additional","affiliation":[{"name":"University of Washington; Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School; Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Freeman","sequence":"additional","affiliation":[{"name":"Harvard Medical School; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,23]]},"reference":[{"issue":"Suppl 2","key":"10.1002\/mus.25264-BIB0001|mus25264-cit-0001","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.2337\/diab.46.2.S82","article-title":"Aldose reductase inhibitors: the end of an era or the need for different trial designs?","volume":"46","author":"Pfeifer","year":"1997","journal-title":"Diabetes"},{"key":"10.1002\/mus.25264-BIB0002|mus25264-cit-0002","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00125-003-1086-8","article-title":"Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients","volume":"46","author":"Malik","year":"2003","journal-title":"Diabetologia"},{"key":"10.1002\/mus.25264-BIB0003|mus25264-cit-0003","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db07-0285","article-title":"Surrogate markers of small fiber damage in human diabetic neuropathy","volume":"56","author":"Quattrini","year":"2007","journal-title":"Diabetes"},{"key":"10.1002\/mus.25264-BIB0004|mus25264-cit-0004","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jdiacomp.2015.01.011","article-title":"Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance","volume":"29","author":"Zilliox","year":"2015","journal-title":"J Diabetes Complications"},{"key":"10.1002\/mus.25264-BIB0005|mus25264-cit-0005","unstructured":"Department of Health and Human Services, Food and Drug Administration Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009 http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf 2015"},{"key":"10.1002\/mus.25264-BIB0006|mus25264-cit-0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1037\/h0040957","article-title":"Construct validity in psychological tests","volume":"52","author":"Cronbach","year":"1955","journal-title":"Psychol Bull"},{"key":"10.1002\/mus.25264-BIB0007|mus25264-cit-0007","unstructured":"Department of Health and Human Services, Food and Drug Administration Guidance for industry and FDA staff: qualification process for drug development tools. 2014 http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm230597.pdf 2015"},{"key":"10.1002\/mus.25264-BIB0008|mus25264-cit-0008","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1002\/mus.25264-BIB0009|mus25264-cit-0009","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1002\/mus.25264-BIB0010|mus25264-cit-0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","article-title":"Psychometric evaluation of the Gynecologic\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynelol Cancer"},{"key":"10.1002\/mus.25264-BIB0011|mus25264-cit-0011","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","article-title":"The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy","volume":"7","author":"Vinik","year":"2005","journal-title":"Diabetes Technol Ther"},{"key":"10.1002\/mus.25264-BIB0012|mus25264-cit-0012","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.ejca.2013.04.004","article-title":"Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)","volume":"49","author":"Binda","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1002\/mus.25264-BIB0013|mus25264-cit-0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002820-198802000-00005","article-title":"High-dose cisplatin-related peripheral neuropathy","volume":"11","author":"Ostchega","year":"1988","journal-title":"Cancer Nurs"},{"key":"10.1002\/mus.25264-BIB0014|mus25264-cit-0014","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1188\/10.CJON.E22-E28","article-title":"Patient perceptions associated with chemotherapy-induced peripheral neuropathy","volume":"14","author":"Tofthagen","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1002\/mus.25264-BIB0015|mus25264-cit-0015","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1097\/NCC.0b013e31820251de","article-title":"Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool","volume":"34","author":"Tofthagen","year":"2011","journal-title":"Cancer Nurs"},{"key":"10.1002\/mus.25264-BIB0016|mus25264-cit-0016","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/mus.25264-BIB0017|mus25264-cit-0017","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2337\/diacare.26.9.2549","article-title":"The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument","volume":"26","author":"Vileikyte","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1002\/mus.25264-BIB0018|mus25264-cit-0018","unstructured":"U.S. Health and Human Services, Food and Drug Administration Clinical Outcome Assessment Compendium http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm459231.htm 2016"},{"key":"10.1002\/mus.25264-BIB0019|mus25264-cit-0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"issue":"Suppl 1","key":"10.1002\/mus.25264-BIB0020|mus25264-cit-0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-007-9198-0","article-title":"Applying item response theory (IRT) modeling to questionnaire development, evaluation, and refinement","volume":"16","author":"Edelen","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1002\/mus.25264-BIB0021|mus25264-cit-0021","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/193229680800200616","article-title":"German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity","volume":"2","author":"Vinik","year":"2008","journal-title":"J Diabetes Sci Technol"},{"key":"10.1002\/mus.25264-BIB0022|mus25264-cit-0022","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/WCO.0000000000000244","article-title":"Recent advances in familial amyloid polyneuropathy","volume":"28","author":"Freeman","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"10.1002\/mus.25264-BIB0023|mus25264-cit-0023","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/mus.25264-BIB0024|mus25264-cit-0024","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1002\/mus.25264-BIB0025|mus25264-cit-0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"10.1002\/mus.25264-BIB0026|mus25264-cit-0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jns.12120","article-title":"The Val30Met Familial Amyloid Polyneuropathy specific Rasch-built Overall Disability Scale (FAP-RODS)","volume":"20","author":"Pruppers","year":"2015","journal-title":"J Peripher Nerv Syst"},{"key":"10.1002\/mus.25264-BIB0027|mus25264-cit-0027","volume-title":"Clinical Trials in Neurology","author":"McDermott","year":"2012"},{"key":"10.1002\/mus.25264-BIB0028|mus25264-cit-0028","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00400697","article-title":"A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population","volume":"36","author":"Young","year":"1993","journal-title":"Diabetologia"},{"key":"10.1002\/mus.25264-BIB0029|mus25264-cit-0029","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0168-8227(98)00005-9","article-title":"A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy","volume":"39","author":"Lunetta","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1002\/mus.25264-BIB0030|mus25264-cit-0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/diacare.24.2.250","article-title":"Simple screening tests for peripheral neuropathy in the diabetes clinic","volume":"24","author":"Perkins","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1002\/mus.25264-BIB0031|mus25264-cit-0031","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.clinthera.2005.08.002","article-title":"Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy","volume":"27","author":"Bastyr","year":"2005","journal-title":"Clin Ther"},{"key":"10.1002\/mus.25264-BIB0032|mus25264-cit-0032","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1055-3290(98)80048-4","article-title":"The reliability and validity of the subjective peripheral neuropathy screen","volume":"9","author":"McArthur","year":"1998","journal-title":"J Assoc Nurses AIDS Care"},{"key":"10.1002\/mus.25264-BIB0033|mus25264-cit-0033","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/13550280500384966","article-title":"Clinical validation of the NeuroScreen","volume":"11","author":"Ellis","year":"2005","journal-title":"J Neurovirol"},{"key":"10.1002\/mus.25264-BIB0034|mus25264-cit-0034","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF01845761","article-title":"Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study","volume":"4","author":"Fossa","year":"1996","journal-title":"Support Care Cancer"},{"key":"10.1002\/mus.25264-BIB0035|mus25264-cit-0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1002\/mus.25264-BIB0036|mus25264-cit-0036","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","article-title":"Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer","volume":"5","author":"Leonard","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1002\/mus.25264-BIB0037|mus25264-cit-0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"}],"container-title":["Muscle & Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25264","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/mus.25264\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T15:39:28Z","timestamp":1534347568000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/mus.25264"}},"subtitle":["Symptom-Based Measures in Neuropathy"],"short-title":[],"issued":{"date-parts":[[2016,12,23]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/mus.25264","archive":["Portico"],"relation":{},"ISSN":["0148-639X"],"issn-type":[{"value":"0148-639X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12,23]]}}}